| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
Department of Pediatrics [J. W., S. L. C.] and The Robert H. Lurie Comprehensive Cancer Center [Q-W. Y., S. L., Y. T., H. R. S., A. C.], Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60614
Tumor angiogenesis, a major requirement for tumor outgrowth and metastasis, is regulated by pro- and antiangiogenic factors. Methylation-associated inactivation of the angiogenesis inhibitor thrombospondin-1 (TSP-1) has been observed recently in some adult tumors. To investigate the role of TSP-1 in pediatric cancer, we examined its pattern of expression and mechanisms of regulation in neuroblastoma (NB). TSP-1 was silenced in a subset of undifferentiated, advanced-stage tumors and NB cell lines. In contrast, most localized tumors expressed this angiogenesis inhibitor, and a significant correlation between morphological evidence of neuroblast differentiation and TSP-1 expression was observed. Luciferase assays demonstrated the presence of nuclear factors required for TSP-1 transcription in both TSP-1-positive and -negative cell lines, but no correlation between TSP-1 promoter activity and the level of TSP-1 mRNA expression was seen. Our studies indicate that the transcriptional silencing of TSP-1 was caused by methylation. TSP-1 promoter methylation was detected in all of the NB cell lines lacking TSP-1 mRNA and in 37% of the NB clinical tumors analyzed. Furthermore, treatment with the demethylating agent, 5-Aza-2'-deoxycytidine (5-Aza-dC), restored TSP-1 expression in NB cell lines. Disrupting methylation with 5-Aza-dC also led to significant inhibition of NB in vivo and re-expression of TSP-1 in a subset of NB xenografts. These results suggest that 5-Aza-dC inhibits NB growth by augmenting the expression of TSP-1 along with other genes that suppress tumor growth. Demethylating agents may prove to be effective candidates for the treatment of children with NB.
This article has been cited by other articles:
![]() |
Q. Yang, C. M. Kiernan, Y. Tian, H. R. Salwen, A. Chlenski, B. A. Brumback, W. B. London, and S. L. Cohn Methylation of CASP8, DCR2, and HIN-1 in Neuroblastoma Is Associated with Poor Outcome Clin. Cancer Res., June 1, 2007; 13(11): 3191 - 3197. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Yang, Y. Tian, S. Liu, R. Zeine, A. Chlenski, H. R. Salwen, J. Henkin, and S. L. Cohn Thrombospondin-1 Peptide ABT-510 Combined with Valproic Acid Is an Effective Antiangiogenesis Strategy in Neuroblastoma Cancer Res., February 15, 2007; 67(4): 1716 - 1724. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-J. Lih, W. Wei, and S. N. Cohen Txr1: a transcriptional regulator of thrombospondin-1 that modulates cellular sensitivity to taxanes Genes & Dev., August 1, 2006; 20(15): 2082 - 2095. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Wang, S. Diskin, E. Rappaport, E. Attiyeh, Y. Mosse, D. Shue, E. Seiser, J. Jagannathan, S. Shusterman, M. Bansal, et al. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res., June 15, 2006; 66(12): 6050 - 6062. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M.E.I. Hellebrekers, K.-W. Jair, E. Vire, S. Eguchi, N. T.H. Hoebers, M. F. Fraga, M. Esteller, F. Fuks, S. B. Baylin, M. van Engeland, et al. Angiostatic activity of DNA methyltransferase inhibitors. Mol. Cancer Ther., February 1, 2006; 5(2): 467 - 475. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Misawa, J. Inoue, Y. Sugino, H. Hosoi, T. Sugimoto, F. Hosoda, M. Ohki, I. Imoto, and J. Inazawa Methylation-Associated Silencing of the Nuclear Receptor 1I2 Gene in Advanced-Type Neuroblastomas, Identified by Bacterial Artificial Chromosome Array-Based Methylated CpG Island Amplification Cancer Res., November 15, 2005; 65(22): 10233 - 10242. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Moon, F. G. Bottone Jr., M. F. McEntee, and T. E. Eling Suppression of tumor cell invasion by cyclooxygenase inhibitors is mediated by thrombospondin-1 via the early growth response gene Egr-1 Mol. Cancer Ther., October 1, 2005; 4(10): 1551 - 1558. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Morowitz, R. Barr, Q. Wang, R. King, N. Rhodin, B. Pawel, H. Zhao, S. A. Erickson, G. S. Sheppard, J. Wang, et al. Methionine Aminopeptidase 2 Inhibition Is an Effective Treatment Strategy for Neuroblastoma in Preclinical Models Clin. Cancer Res., April 1, 2005; 11(7): 2680 - 2685. [Abstract] [Full Text] [PDF] |
||||
![]() |
C D E Margetts, D Astuti, D C Gentle, W N Cooper, A Cascon, D Catchpoole, M Robledo, H P H Neumann, F Latif, and E R Maher Epigenetic analysis of HIC1, CASP8, FLIP, TSP1, DCR1, DCR2, DR4, DR5, KvDMR1, H19 and preferential 11p15.5 maternal-allele loss in von Hippel-Lindau and sporadic phaeochromocytomas Endocr. Relat. Cancer, March 1, 2005; 12(1): 161 - 172. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Yang, P. Zage, D. Kagan, Y. Tian, R. Seshadri, H. R. Salwen, S. Liu, A. Chlenski, and S. L. Cohn Association of Epigenetic Inactivation of RASSF1A with Poor Outcome in Human Neuroblastoma Clin. Cancer Res., December 15, 2004; 10(24): 8493 - 8500. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Yang, S. Liu, Y. Tian, C. Hasan, D. Kersey, H. R. Salwen, A. Chlenski, E. J. Perlman, and S. L. Cohn Methylation-Associated Silencing of the Heat Shock Protein 47 Gene in Human Neuroblastoma Cancer Res., July 1, 2004; 64(13): 4531 - 4538. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |